Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
Fiche publication
Date publication
septembre 2015
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe
Tous les auteurs :
Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K
Lien Pubmed
Résumé
There is an urgent need for qualified predictive biomarkers of sensitivity for the treatments used in patients with castration-resistant prostate cancer (CRPC). We attempted to identify ready-to-use clinical predictors of improved outcome in metastatic CRPC (mCRPC) patients treated with next generation androgen receptor (AR) axis targeted drugs.
Mots clés
Adult, Aged, Androgen Antagonists, therapeutic use, Antineoplastic Agents, Hormonal, therapeutic use, Disease-Free Survival, France, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Phenylthiohydantoin, analogs & derivatives, Proportional Hazards Models, Prostatic Neoplasms, Castration-Resistant, drug therapy, Receptors, Androgen, drug effects, Retrospective Studies, Signal Transduction, drug effects, Time Factors, Treatment Outcome
Référence
Eur. J. Cancer. 2015 Sep;51(14):1946-52